LONDON--Danish pharmaceuticals group Novo Nordisk A/S (NOVO-B.KO) Wednesday said it has signed an agreement with U.S. drug group Janssen Biotech, Inc. for Janssen to acquire an exclusive global license to further develop and commercializes a clinical program focused on therapy within autoimmune diseases.

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Novo Nordisk Charts.